10th Jan '17
ZedScan’s clinical benefits to be featured at two colposcopy conferences in Paris
Zilico’s pioneering cervical cancer diagnostic system ZedScan™, will be highlighted in Paris this week at two clinical colposcopy symposiums.
On Wednesday 11th January, Zilico will be exhibiting at the European Federation Colposcopy (EFC) annual congress, being held at the Centre International de Conférence Faculté de Jussieu.
The event will focus on quality standards and practice within colposcopy. Professor John Tidy, Consultant Gynaecological Oncologist, Royal Hallamshire Hospital in Sheffield, has been invited to speak on, ‘Adjunctive Colposcopic Technologies’ and will feature ZedScan.
EFC President-elect, Dr Charles Redman, who is also using ZedScan as part of routine procedure at the University Hospitals of North Midlands NHS Trust, will close the session.
On 14th January, Dr Charles Muszynski, who has recently completed an evaluation of ZedScan will present on the clinical and performance improvements he had experienced, including a significant increase in detection of HG disease especially evident in patients with a low-grade cytology referral.
Dr Muszynski’s presentation is part of the Annual French Colposcopy Society meeting, the SFCPCV congress, being held at the Institut Pasteur. Zilico will be at the event to support its French partner, Luneau, and the ZedScan system will be available for demonstration on their stand throughout the two days.
ZedScan is a portable, handheld device that uses patented Electrical Impedance Spectroscopy (EIS) to detect the development of pre-cancerous abnormalities of the cervix, known as cervical intraepithelial neoplasia (CIN).
It is now used in many hospitals across the globe as an adjunct to the current diagnostic process to offer a more accurate diagnosis in real time and assist clinicians with improved patient management.